[HTML][HTML] Molecular mechanisms and therapeutic targets for diabetic kidney disease
Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …
The epidemiology of diabetic kidney disease
EK Hoogeveen - Kidney and Dialysis, 2022 - mdpi.com
Globally, the incidence and prevalence of diabetes mellitus has risen dramatically, owing
mainly to the increase in type 2 diabetes mellitus (T2DM). In 2021, 537 million people …
mainly to the increase in type 2 diabetes mellitus (T2DM). In 2021, 537 million people …
What's new in the molecular mechanisms of diabetic kidney disease: recent advances
K Watanabe, E Sato, E Mishima, M Miyazaki… - International journal of …, 2022 - mdpi.com
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease, including end-
stage kidney disease, and increases the risk of cardiovascular mortality. Although the …
stage kidney disease, and increases the risk of cardiovascular mortality. Although the …
Ion channels and channelopathies in glomeruli
An essential step in renal function entails the formation of an ultrafiltrate that is delivered to
the renal tubules for subsequent processing. This process, known as glomerular filtration, is …
the renal tubules for subsequent processing. This process, known as glomerular filtration, is …
Cardiorenal benefits of finerenone: protecting kidney and heart
Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of
develo** cardiovascular (CV) complications despite treatment with renin-angiotensin …
develo** cardiovascular (CV) complications despite treatment with renin-angiotensin …
[HTML][HTML] DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …
obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular …
NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells
J Chen, H Peng, C Chen, Y Wang, T Sang, Z Cai… - Life sciences, 2022 - Elsevier
Aims Our previous studies showed that the nonsteroidal anti-inflammatory drug-activated
gene-1, or growth differentiation factor-15 (NAG-1/GDF15) inhibits obesity and diabetes in …
gene-1, or growth differentiation factor-15 (NAG-1/GDF15) inhibits obesity and diabetes in …
[HTML][HTML] A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 …
FNU Jyotsna, K Mahfooz, T Patel, FNU Parshant… - Cureus, 2023 - ncbi.nlm.nih.gov
The purpose of this study is to assess the safety and efficacy of finerenone therapy in type 2
diabetes mellitus (T2DM) patients with cardiovascular and chronic renal diseases. This meta …
diabetes mellitus (T2DM) patients with cardiovascular and chronic renal diseases. This meta …
Slowing the progression of diabetic kidney disease
O Blazek, GL Bakris - Cells, 2023 - mdpi.com
Diabetes is the most frequent cause of kidney disease that progresses to end-stage renal
disease worldwide, and diabetic kidney disease is significantly related to unfavorable …
disease worldwide, and diabetic kidney disease is significantly related to unfavorable …
Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes
Background In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and
heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration …
heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration …